216 related articles for article (PubMed ID: 24739978)
1. Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.
van der Velden MV; Geisberger A; Dvorak T; Portsmouth D; Fritz R; Crowe BA; Herr W; Distler E; Wagner EM; Zeitlinger M; Sauermann R; Stephan C; Ehrlich HJ; Barrett PN; Aichinger G
Clin Vaccine Immunol; 2014 Jun; 21(6):867-76. PubMed ID: 24739978
[TBL] [Abstract][Full Text] [Related]
2. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.
van der Velden MV; Aichinger G; Pöllabauer EM; Löw-Baselli A; Fritsch S; Benamara K; Kistner O; Müller M; Zeitlinger M; Kollaritsch H; Vesikari T; Ehrlich HJ; Barrett PN
Vaccine; 2012 Sep; 30(43):6127-35. PubMed ID: 22884662
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population.
van der Velden MV; Fritz R; Pöllabauer EM; Portsmouth D; Howard MK; Kreil TR; Dvorak T; Fritsch S; Vesikari T; Diez-Domingo J; Richmond P; Lee BW; Kistner O; Ehrlich HJ; Barrett PN; Aichinger G
J Infect Dis; 2014 Jan; 209(1):12-23. PubMed ID: 24041789
[TBL] [Abstract][Full Text] [Related]
4. Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults.
Gillard P; Chu DW; Hwang SJ; Yang PC; Thongcharoen P; Lim FS; Dramé M; Walravens K; Roman F
BMC Infect Dis; 2014 Mar; 14():142. PubMed ID: 24628789
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
Tambyah PA; Wilder-Smith A; Pavlova BG; Barrett PN; Oh HM; Hui DS; Yuen KY; Fritsch S; Aichinger G; Loew-Baselli A; van der Velden M; Maritsch F; Kistner O; Ehrlich HJ
Vaccine; 2012 Jan; 30(2):329-35. PubMed ID: 22080174
[TBL] [Abstract][Full Text] [Related]
6. Combined administration of MF59-adjuvanted A/H5N1 prepandemic and seasonal influenza vaccines: long-term antibody persistence and robust booster responses 1 year after a one-dose priming schedule.
Lopez P; Caicedo Y; Sierra A; Tilman S; Clemens R; Banzhoff A
Clin Vaccine Immunol; 2013 May; 20(5):753-8. PubMed ID: 23536690
[TBL] [Abstract][Full Text] [Related]
7. Induction of cross-neutralizing antibody against H5N1 virus after vaccination with seasonal influenza vaccine in COPD patients.
Kositanont U; Wongsurakiat P; Pooruk P; Maranetra N; Puthavathana P
Viral Immunol; 2010 Jun; 23(3):329-34. PubMed ID: 20565296
[TBL] [Abstract][Full Text] [Related]
8. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.
Herbinger KH; von Sonnenburg F; Nothdurft HD; Perona P; Borkowski A; Fragapane E; Nicolay U; Clemens R
Hum Vaccin Immunother; 2014; 10(1):92-9. PubMed ID: 24047817
[TBL] [Abstract][Full Text] [Related]
10. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.
Rudenko L; Naykhin A; Donina S; Korenkov D; Petukhova G; Isakova-Sivak I; Losev I; Stukova M; Erofeeva M; Nikiforova A; Power M; Flores J
Hum Vaccin Immunother; 2015; 11(12):2839-48. PubMed ID: 26697973
[TBL] [Abstract][Full Text] [Related]
11. A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel®].
Plosker GL
Drugs; 2012 Jul; 72(11):1543-57. PubMed ID: 22788239
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
Crowe BA; Brühl P; Gerencer M; Schwendinger MG; Pilz A; Kistner O; Koelling-Schlebusch K; Aichinger G; Singer J; Zeitlinger M; Müller M; Ehrlich H; Barrett PN
Vaccine; 2010 Dec; 29(2):166-73. PubMed ID: 21055500
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.
Aichinger G; Grohmann-Izay B; van der Velden MV; Fritsch S; Koska M; Portsmouth D; Hart MK; El-Amin W; Kistner O; Barrett PN
Clin Vaccine Immunol; 2015 Jan; 22(1):46-55. PubMed ID: 25355797
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP
Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trial.
Bethell D; Saunders D; Jongkaewwattana A; Kramyu J; Thitithayanont A; Wiboon-ut S; Yongvanitchit K; Limsalakpetch A; Kum-Arb U; Uthaimongkol N; Garcia JM; Timmermans AE; Peiris M; Thomas S; Engering A; Jarman RG; Mongkolsirichaikul D; Mason C; Khemnu N; Tyner SD; Fukuda MM; Walsh DS; Pichyangkul S
PLoS One; 2013; 8(3):e59674. PubMed ID: 23555741
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial.
Langley JM; Frenette L; Jeanfreau R; Halperin SA; Kyle M; Chu L; McNeil S; Dramé M; Moris P; Fries L; Vaughn DW
Vaccine; 2015 Jan; 33(4):559-67. PubMed ID: 25448092
[TBL] [Abstract][Full Text] [Related]
17. A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults.
Nagai H; Ikematsu H; Tenjinbaru K; Maeda A; Dramé M; Roman FP
BMC Infect Dis; 2010 Nov; 10():338. PubMed ID: 21108818
[TBL] [Abstract][Full Text] [Related]
18. A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.
Sabarth N; Savidis-Dacho H; Schwendinger MG; Brühl P; Portsmouth D; Crowe BA; Kistner O; Barrett PN; Kreil TR; Howard MK
Vaccine; 2012 Aug; 30(37):5533-40. PubMed ID: 22749797
[TBL] [Abstract][Full Text] [Related]
19. The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study.
Wei SH; Liu MT; Tsai YC; Liao CH; Chen CM; Wang WY; Huang YL; Chang FY; Chou P
BMC Infect Dis; 2014 Nov; 14():587. PubMed ID: 25394941
[TBL] [Abstract][Full Text] [Related]
20. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]